Many applications—from drug discovery and diagnostics to cell engineering and gene modulation—require delivering biomolecules into large numbers of cells and rapidly evaluating the outcomes. The ...

If you have been following AbbVie (ABBV), the company’s latest move might sway your decision on whether to stick with or jump into the stock. AbbVie just submitted a New Drug Application to the FDA ...

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but the long-term failure of the grafted veins is a persistent challenge.

On Thursday, September 4, 2025, Codexis (NASDAQ:CDXS) presented at the Cantor Global Healthcare Conference, outlining its strategic focus on enzymatic synthesis for siRNA therapeutics. The company ...

Codexis is considering shifting from enzyme supply to ECO Synthesis. Click here to find out why CDXS stock is a Hold.

China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop new siRNA candidate, 2MW7141.

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the National Medical Products Administration of China (NMPA ...

Argo and Novartis expand collaboration, focusing on cardiovascular assets, including siRNA therapeutics for severe hypertriglyceridemia and mixed dyslipidemia. Novartis gains licensing rights and ...